Rapid tumor lysis of HLA-I–matched KRASG12V cell lines without reactivity to KRASWT was observed for AV11a-c–engineered CD8+ T cells with 50% killing (KT50) achieved at less than 50 hours (Figure 5E). This evidence concerns the gene CD8A and neoplasm.